Catch up on news and trends in healthcare
2012
Q1 Quarterly Pipeline Report
(January-February-March)
Medications to watch: Medications to watch: Vismodegib, Mulsevo® (semuloparin) and Tofacitinib
Q2 Quarterly Pipeline Report
(April-May-June)
Medications to watch: Vismodegib, Mulsevo® (semuloparin) and Tofacitinib
2011
Q4 Quarterly Pipeline Report
(October-November-December)
Medications to watch: Uplyso (taliglucerase alfa), Axitinib, and Ivacaftor (VX-770)
Q3 Quarterly Pipeline Report
(July-August-September)
Medications to watch: Crizotinib, Ruxolitinib and Teriflunomide
Q2 Quarterly Pipeline Report
(April-May-June)
Nulojix (belatacept), Omapro™ (omacetaxine) and Gattex® (teduglutide)
Q1 Quarterly Pipeline Report
(January-February-March)
Medications to watch: Abiraterone, Hematide™ (peginesatide) and Aflibercept (VEGF Trap-Eye)
2010
Q3 Quarterly Pipeline Report
(July-August-September)
Medications to watch: Ipilimumab, Pasireotide (SOM230) and Zactima® (vandetanib)
Q2 Quarterly Pipeline Report
(April-May-June)
Medications to watch: Eribulin, Denufosol, Tasigna® (nilotinib) and Sprycel® (dasatinib)
Q1 Quarterly Pipeline Report
(January-February-March)
Medications to watch: Egrifta (tesamorelin), Ridaforolimus, Dimebon (latrepirdine) and Huntexil® (pridopidine)
2009
Q4 Quarterly Pipeline Report
(October-November-December)
Medications to watch: Votrient™(pazopanib), Replagal® (agalsidase alfa) and Tafamidis
Q3 Quarterly Pipeline Report
(July-August-September)
Medications to watch: Omacetaxine, Velaglucerase alfa and Benlysta™ (belimumab)
